Tianjin Lisheng Pharmaceutical Co.,Ltd.

Equities

002393

CNE100000NJ9

Pharmaceuticals

End-of-day quote Shenzhen S.E. 06:00:00 2024-04-18 pm EDT 5-day change 1st Jan Change
25.01 CNY +1.83% Intraday chart for Tianjin Lisheng Pharmaceutical Co.,Ltd. +0.81% -4.18%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Tianjin Lisheng Pharmaceutical Co.,Ltd. Proposes Cash Dividend for the Year 2023 CI
Tianjin Lisheng Pharmaceutical's 2023 Profit Surges on Gains from Asset Disposals; Shares Jump 4% MT
Tianjin Lisheng Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Lisheng Pharmaceutical Buys 65% Stake in Qingchun Kangyuan Pharmaceutical for 137 Million Yuan; Shares Up 3% MT
Tianjin Arm Lisheng Pharmaceutical To Buy Chinese Medicine Firm Jiangxi Qingchun Kangyuan MT
Tianjin Lisheng Pharmaceutical Co.,Ltd. agreed to acquire 65% stake in Jiangxi Qingchun Kangyuan Pharmaceutical Co., Ltd. from Jiangxi Qingchun Kangyuan Group Co., Ltd. and Jiangxi Qingchun Kangyuan Chinese Medicine Co., Ltd. for approximately CNY 140 million. CI
Tianjin Lisheng Pharma Setting Up Venture Capital Fund MT
Lisheng Pharmaceutical and Lisheng Investment Enter into the Partnership Agreement with Bozheng Capital, Tianjin Jinjia and Tianjin Handeway CI
Tianjin Development to Vote Dec. 5 on Lisheng Pharma's Sale of Tianjin Pharmaceutical Finance Stake MT
Tianjin Lisheng Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited agreed to acquire additional 15% stake in Tianjin Pharmaceutical Group Finance Co., Ltd from Tianjin Lisheng Pharmaceutical Co.,Ltd. for CNY 87.8 million. CI
Lisheng Pharmaceutical's H1 Attributable Profit Jumps MT
Tianjin Lisheng Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Lisheng Pharmaceutical Subscribes for 20 Million Yuan Wealth Management Product MT
Lisheng Pharma to Receive 247.9 Million Yuan for Relocation MT
Lisheng Pharmaceutical Eyes 247.9 Million Yuan from Potential Land Resumption Deal MT
Tianjin Lisheng Pharmaceutical Co.,Ltd. Announces 2022 Final Profit Distribution Plan to Be Implemented (A Shares), Payment Date Is 30 June 2023 CI
Tianjin Lisheng Pharma Gets Nod For Febuxostat Active Pharma Ingredient in China MT
Lisheng Pharma Unit's Drug Passes Regulatory Evaluation MT
Tianjin Lisheng Pharmaceutical's Q1 Attributable Profit Increases MT
Tianjin Lisheng Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Lisheng Pharmaceutical's Audited 2022 Profit Marginally Higher Than Unaudited Results MT
Tianjin Lisheng Pharmaceutical Co., Ltd. Announces the Profit Distribution Proposal for the Year 2022 CI
Tianjin Lisheng Pharmaceutical's 2022 Attributable Profit Falls 23.5% MT
Tianjin Lisheng Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Chart Tianjin Lisheng Pharmaceutical Co.,Ltd.
More charts
Tianjin Lisheng Pharmaceutical Co., Ltd. is a China-based company, principally engaged in the manufacture and distribution of chemical drugs. The Company's major products are tablets, hard capsules, pills, free-dry powder injections, water injections and raw drugs, including drugs for cardio and cerebral vascular systems, anti-infection drugs and hormone drugs, among others. It distributes its products mainly within domestic markets.
Calendar
More about the company
  1. Stock Market
  2. Equities
  3. 002393 Stock
  4. News Tianjin Lisheng Pharmaceutical Co.,Ltd.
  5. Lisheng Pharmaceutical's January-September Profit Increases 15%